871816-09-0

Basic information

• Product Name: 1-[(3-hydroxyphenyl)methyl]-(5S)-(1H-imidazol-1-ylmethyl)-2-pyrrolidinone
• Synonyms: 1-[(3-hydroxyphenyl)methyl]-(5S)-(1H-imidazol-1-ylmethyl)-2-pyrrolidinone
• CAS NO: 871816-09-0
• Molecular Weight: 271.319
• Mol File: 871816-09-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-[(3-hydroxyphenyl)methyl]-(5S)-(1H-imidazol-1-ylmethyl)-2-pyrrolidinone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(3-hydroxyphenyl)methyl]-(5S)-(1H-imidazol-1-ylmethyl)-2-pyrrolidinone(871816-09-0)
• EPA Substance Registry System: 1-[(3-hydroxyphenyl)methyl]-(5S)-(1H-imidazol-1-ylmethyl)-2-pyrrolidinone(871816-09-0)

Safety Data

• Hazardous Substances Data: 871816-09-0(Hazardous Substances Data)

Upstream product

• 1700-31-8 3-benzyloxybenzyl bromide 
• 1700-30-7 (3-(benzyloxy)phenyl)methanol 
• 4931-66-2 methyl (S)-pyroglutamate 
• 98-79-3 L-Pyroglutamic acid 
• 871816-04-5 4-methylbenzenesulfonic acid [5-oxo-1-[[3-(phenylmethoxy)phenyl]methyl]-(2S)-pyrrolidinyl]methyl ester 
• 871816-02-3 (5S)-(hydroxymethyl)-1-[[3-(phenylmethoxy)phenyl]methyl]-2-pyrrolidinone 
• 1308718-80-0 (2S)-5-oxo-1-[(3-phenylmethoxyphenyl)methyl]pyrrolidine-2-carboxylic acid methyl ester 
• 871816-07-8 (5S)-(1H-imidazol-1-ylmethyl)-1-[[3-(phenylmethoxy)phenyl]methyl]-2-pyrrolidinone 

Relevant articles and documents

Synthesis, in silico docking experiments of new 2-pyrrolidinone derivatives and study of their anti-inflammatory activity

A new class of 2-pyrrolidinone derivatives was designed, synthesized, and tested for their antioxidant and anti-inflammatory activities. The compounds were evaluated for their inhibitory activity against LOX. The most potent among them, 14d [IC50 0.08 (±0.005) mM], and 14e [IC50 0.0705 (±0.003) mM], were also tested in vivo. The compound 14d induced equipotent inhibition against rat paw edema, which is very close to the effect produced by the commonly used standard, namely indomethacin (47%). The LOX inhibitory activity of the compound 14e proceeds in parallel to the % inhibitory value of lipid peroxidation meaning that this LOX inhibitory activity is supported by the lipid peroxidation inhibition. The molecular features that govern their bioactivity were explored through in silico docking experiments. The results showed that acidic moieties must be placed in certain distance and orientation in the active site of LOX enzyme in order to productively exhibit inhibitory activity. In addition, the 2-pyrrolidinone template significantly contributes in the inhibitory properties of the new compounds.